A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
Pyrotinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer:a Randomised, Double-blind, Multicentre, Phase 3 Trial
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Listed as NCT02973737, this PHASE3 trial focuses on HER2 Positive Metastatic Breast Cancer and remains ongoing. Sponsored by Jiangsu HengRui Medicine Co., Ltd., it has been updated 9 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Nov 2024 — Present [monthly]
Unknown PHASE3
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Jan 2021 — Nov 2022 [monthly]
Unknown Status PHASE3
▶ Show 4 earlier versions
-
Jan 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Jan 2018 [monthly]
Recruiting PHASE3
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu HengRui Medicine Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .